A recent meta-analysis of response efficacy to PD-1 and PD-L1 inhibitors across cancer types identified that targeting PD-1, especially in combination with chemotherapy, can result in improved response rates over that of similar PD-L1 combinations [46]. The gene discussed is CD274; the disease is cancer.